Your browser is no longer supported. Please, upgrade your browser.
JAZZ Jazz Pharmaceuticals plc weekly Stock Chart
JAZZ [NASD]
Jazz Pharmaceuticals plc
Index- P/E23.97 EPS (ttm)5.93 Insider Own2.50% Shs Outstand61.32M Perf Week-0.98%
Market Cap8.71B Forward P/E10.16 EPS next Y13.98 Insider Trans0.15% Shs Float58.77M Perf Month-4.34%
Income364.70M PEG1.52 EPS next Q2.96 Inst Own95.90% Short Float3.19% Perf Quarter-13.98%
Sales1.85B P/S4.71 EPS this Y-15.40% Inst Trans-2.42% Short Ratio2.87 Perf Half Y-19.82%
Book/sh50.06 P/B2.84 EPS next Y7.51% ROA9.80% Target Price186.22 Perf Year1.10%
Cash/sh17.35 P/C8.19 EPS next 5Y15.73% ROE18.20% 52W Range130.15 - 184.00 Perf YTD5.53%
Dividend- P/FCF11.18 EPS past 5Y4.60% ROI9.80% 52W High-23.25% Beta0.95
Dividend %- Quick Ratio4.20 Sales past 5Y22.50% Gross Margin93.50% 52W Low8.51% ATR5.69
Employees1210 Current Ratio4.30 Sales Q/Q14.00% Oper. Margin30.80% RSI (14)40.73 Volatility3.86% 3.47%
OptionableYes Debt/Eq0.53 EPS Q/Q133.40% Profit Margin28.10% Rel Volume0.74 Prev Close142.10
ShortableYes LT Debt/Eq0.52 EarningsNov 06 AMC Payout0.00% Avg Volume651.82K Price141.22
Recom2.00 SMA20-2.67% SMA50-7.19% SMA200-12.75% Volume53,770 Change-0.62%
Nov-08-18Reiterated B. Riley FBR Buy $219 → $190
Aug-08-18Reiterated Stifel Buy $180 → $205
Jul-11-18Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-23-18Reiterated H.C. Wainwright Neutral $150 → $160
Mar-19-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-03-18Initiated Leerink Partners Outperform $180
Dec-05-17Reiterated Mizuho Neutral $144 → $150
Nov-10-17Resumed H.C. Wainwright Neutral $150
Nov-08-17Reiterated RBC Capital Mkts Outperform $210 → $195
Oct-19-17Initiated FBR & Co. Buy $206
Oct-05-17Initiated Morgan Stanley Equal-Weight $155
Sep-28-17Initiated Goldman Neutral $165
Aug-25-17Initiated H.C. Wainwright Neutral $144
May-31-17Reiterated Mizuho Neutral $150 → $144
May-15-17Initiated RBC Capital Mkts Outperform $210
Apr-06-17Downgrade Mizuho Buy → Neutral $162 → $150
Mar-21-17Reiterated Mizuho Buy $152 → $162
Feb-21-17Reiterated Mizuho Buy $127 → $152
Nov-09-16Reiterated Mizuho Buy $185 → $127
Aug-10-16Reiterated Mizuho Buy $195 → $185
Dec-11-18 05:44PM  Jazz (JAZZ) Increases Share Buyback Authorization by $400M Zacks
08:22AM  The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings Benzinga
05:00AM  All That JAZZ MoneyShow
12:04AM  Jazz Pharmaceuticals Public Limited Company (JAZZ): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-10-18 04:10PM  Jazz Pharmaceuticals Announces Share Repurchase Program Authorization Increase of $400 Million PR Newswire
Dec-05-18 11:45AM  Is Jazz Pharmaceuticals plcs (NASDAQ:JAZZ) CEO Salary Justified? Simply Wall St.
Nov-29-18 08:30AM  Report: Exploring Fundamental Drivers Behind Jazz Pharmaceuticals, 58, Encore Capital Group, Churchill Downs, Addus HomeCare, and Huntington Ingalls Industries New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
08:00AM  Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for the Treatment of Idiopathic Hypersomnia PR Newswire
Nov-28-18 08:00AM  Jazz Pharmaceuticals to Highlight Hematology Research at ASH 2018 Annual Meeting PR Newswire
Nov-14-18 03:47PM  Edited Transcript of JAZZ earnings conference call or presentation 6-Nov-18 9:30pm GMT Thomson Reuters StreetEvents -5.91%
Nov-13-18 06:26AM  Moving Average Crossover Alert: Jazz Pharmaceuticals (JAZZ) Zacks
Nov-09-18 02:00AM  Jazz Pharmaceuticals Submits Marketing Authorization Application to European Medicines Agency for Solriamfetol as a Treatment to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adult Patients with Narcolepsy or Obstructive Sleep Apnea PR Newswire
Nov-08-18 10:09AM  Jazz Pharma (JAZZ) Beats on Q3 Earnings, Lowers Sales View Zacks
Nov-07-18 07:05PM  National Institute for Health and Care Excellence (NICE) Recommends Jazz Pharmaceuticals' Vyxeos® (Daunorubicin and Cytarabine) for Adults with Specific Types of Secondary Acute Myeloid Leukaemia (AML) PR Newswire -14.60%
04:11PM  IBD 50 Pharma Stock Topples As Cancer Drug Lags Expectations Investor's Business Daily
04:05PM  Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences PR Newswire
03:45PM  Why Jazz Pharmaceuticals plc Stock Is Slumping Today Motley Fool
07:09AM  Dow Jones Futures Jump On Election Results; 7 Big Movers On Earnings Investor's Business Daily
Nov-06-18 07:40PM  Jazz Pharmaceuticals (JAZZ) Tops Q3 Earnings Estimates Zacks
06:41PM  Jazz: 3Q Earnings Snapshot Associated Press
05:38PM  This 99 Composite Rating Pharma Tumbled On Quarterly Sales Lag Investor's Business Daily
04:05PM  Jazz Pharmaceuticals Announces Third Quarter 2018 Financial Results PR Newswire
Nov-05-18 11:38AM  Should We Be Delighted With Jazz Pharmaceuticals plcs (NASDAQ:JAZZ) ROE Of 15%? Simply Wall St.
Oct-29-18 10:17AM  Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more American City Business Journals
08:00AM  Jazz Pharmaceuticals Announces FDA Approval of Xyrem® (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients PR Newswire
Oct-23-18 04:05PM  Jazz Pharmaceuticals to Report 2018 Third Quarter Financial Results on November 6, 2018 PR Newswire
Oct-19-18 07:55AM  Detailed Research: Economic Perspectives on W.W. Grainger, Jabil, Grand Canyon Education, Sage Therapeutics, H. B. Fuller, and Jazz Pharmaceuticals What Drives Growth in Today's Competitive Landscape GlobeNewswire
Oct-15-18 08:45AM  Zacks.com highlights: Manulife Financial, Jazz Pharmaceuticals, DaVita, American Axle & Manufacturing Holdings and Huntsman Zacks
Oct-10-18 09:30AM  JAZZ or ZTS: Which Is the Better Value Stock Right Now? Zacks
08:00AM  Jazz Pharmaceuticals Survey Highlights Significant Impact of Excessive Daytime Sleepiness Related to Sleep Apnea PR Newswire
Oct-05-18 10:42AM  How Do Analysts See Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Performing Over The Next Year? Simply Wall St.
Sep-20-18 09:30AM  Is Jazz Pharmaceuticals a Great Stock for Value Investors? Zacks
08:34AM  Is the Options Market Predicting a Spike in Jazz Pharmaceuticals (JAZZ) Stock? Zacks
Sep-17-18 02:46PM  The Week Ahead: Alibaba Investor Day, FedEx Earnings, Eventbrite IPO Benzinga
Sep-11-18 04:05PM  Jazz Pharmaceuticals Announces an Informational Webcast for Investors Related to Vyxeos EU Launch PR Newswire
Sep-06-18 10:28AM  Why Is Jazz (JAZZ) Down 2.4% Since Last Earnings Report? Zacks
Aug-30-18 10:35AM  Is Jazz Pharmaceuticals plcs (NASDAQ:JAZZ) PE Ratio A Signal To Buy For Investors? Simply Wall St.
Aug-29-18 04:05PM  Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences PR Newswire
Aug-27-18 09:27AM  Jazz's (JAZZ) Leukemia Drug Vyxeos Gets Approval in Europe Zacks
02:00AM  Vyxeos® Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia PR Newswire
Aug-21-18 10:41AM  5 Low-Cost Biotech Stocks With High Levels of Growth InvestorPlace
Aug-20-18 10:03AM  8 Undervalued Biotech Stocks to Watch InvestorPlace
Aug-17-18 07:45AM  Edited Transcript of JAZZ earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-13-18 04:48PM  All that Jazz: Growing pharmaceutical company opens new Philadelphia office American City Business Journals
04:05PM  These Five 95+ Composite Rating Stocks Are Just Below Buy Points Investor's Business Daily
Aug-09-18 10:15AM  7 Biotech Stocks With Big Upcoming Catalysts Kiplinger
Aug-08-18 10:21AM  Stocks Fall As Trade War Heats Up; This Top Growth Stock Breaks Out Investor's Business Daily
08:45AM  Jazz Pharma's (JAZZ) Stock Down Despite Q2 Earnings Beat Zacks
Aug-07-18 05:35PM  Jazz: 2Q Earnings Snapshot Associated Press
05:01PM  IBD 50 Stock Jazz Pharma Tops Views, But Profit Outlook Light Investor's Business Daily
04:05PM  Jazz Pharmaceuticals Announces Second Quarter 2018 Financial Results PR Newswire
02:30PM  11 Blue Chips Drive Dow Jones Higher; How Apple Can Hit $1.25 Trillion In Market Cap Investor's Business Daily
02:30PM  Jazz Pharmaceuticals Plc to Host Earnings Call ACCESSWIRE
Aug-06-18 04:15PM  Jazz Pharmaceuticals and MD Anderson Cancer Center Collaborate to Evaluate Potential Treatment Options for Hematologic Malignancies PR Newswire
09:38AM  Jazz Pharma (JAZZ) Q2 Earnings Coming Up: What's in Store? Zacks
08:38AM  Why Earnings Season Could Be Great for Jazz Pharmaceuticals (JAZZ) Zacks
Aug-03-18 08:00AM  CMS Grants New Technology Add-On Payment to Vyxeos® (daunorubicin and cytarabine) Liposome for Injection PR Newswire
Jul-31-18 04:14PM  IBD Stock Of The Day: Jazz Pharma Approaches Buy Point Ahead Of Earnings Investor's Business Daily
Jul-24-18 04:05PM  Jazz Pharmaceuticals to Report 2018 Second Quarter Financial Results on August 7, 2018 PR Newswire
Jul-19-18 04:45PM  Journal of Clinical Oncology publishes pivotal Phase 3 data for Jazz Pharmaceuticals' Vyxeos® (daunorubicin and cytarabine) Liposome for Injection PR Newswire
Jul-18-18 07:20AM  Free Daily Technical Summary Reports on Iovance Biotherapeutics and Three Other Biotech Stocks ACCESSWIRE
Jul-13-18 01:53PM  U.S. court denies Jazz Pharma bid to revive narcolepsy drug patents Reuters
09:57AM  U.S. court denies Jazz Pharma bid to revive patents on narcolepsy drug Reuters
Jul-11-18 03:25PM  Morgan Stanley Downgrades Jazz Pharmaceuticals As Stock Approaches Price Target Benzinga
Jul-09-18 02:00PM  5 Low Price-to-Book Stocks Worth Buying in July InvestorPlace
Jul-06-18 02:36PM  Dermira (DERM) Gains 5% in a Week, Post-Qbrexa Approval Zacks
10:34AM  Aclaris Stock Up on JAK Inhibitor's Encouraging Activity Zacks
Jul-02-18 10:34AM  Jazz Sells Pain Drug Prialt's Rights to TerSera Therapeutics Zacks
Jun-29-18 04:05PM  Jazz Pharmaceuticals Enters Into Agreement with TerSera Therapeutics LLC for Prialt PR Newswire
10:01AM  5 Stocks Near 52-Week High: Is More Upside in the Cards? Zacks
08:15AM  Vyxeos Receives Positive CHMP Opinion for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia PR Newswire
Jun-28-18 10:51AM  Jazz Pharmaceuticals' sNDA for Xyrem Gets Priority Review Zacks
Jun-27-18 04:15PM  Jazz Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Xyrem® (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients PR Newswire
Jun-26-18 12:02PM  Innoviva And Other Great Growth Stocks Simply Wall St.
Jun-25-18 10:31AM  Is Jazz Pharmaceuticals plcs (NASDAQ:JAZZ) Balance Sheet A Threat To Its Future? Simply Wall St.
Jun-19-18 08:55AM  5 Low-Beta Stocks to Buy as Trade Conflict Intensifies Zacks
Jun-18-18 07:32AM  Zacks.com highlights: Jazz Pharmaceuticals, Baxter International, Boise Cascade, Insight Enterprises and Comfort Systems USA Zacks
Jun-15-18 10:03AM  5 Stocks Near 52-Week High With More Room to Run Zacks
09:23AM  5 Best Bargain PEG Stocks That Value Investors Love Zacks
07:09AM  Iovance Biotherapeutics and Three Additional Biotech Stocks on Our Research Desk's Radar ACCESSWIRE
Jun-07-18 08:41AM  Jazz Pharmaceuticals (JAZZ) Up 16.9% Since Earnings Report: Can It Continue? Zacks
Jun-06-18 04:05PM  Jazz Pharmaceuticals to Present at the Goldman Sachs Global Healthcare Conference PR Newswire
04:03PM  Drugmaker Lundbeck to settle U.S. charity probe for $52.6 mln Reuters
Jun-04-18 08:20AM  Report: Exploring Fundamental Drivers Behind Mitel Networks, Celestica, CoreCivic, Inc., Jazz Pharmaceuticals, Open Text, and ChemoCentryx New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jun-03-18 05:00PM  Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sleepiness in Narcolepsy or Obstructive Sleep Apnea PR Newswire
05:00PM  Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data for Xyrem® (sodium oxybate) in Pediatric Patients with Narcolepsy with Cataplexy PR Newswire
May-31-18 08:30AM  New Survey Highlights Lack of Awareness of Neurologic Effects Related to Excessive Sleepiness in Patients with Obstructive Sleep Apnea PR Newswire
May-24-18 04:05PM  Jazz Pharmaceuticals Announces Webcast Discussion of Data to be Presented at APSS PR Newswire
May-22-18 03:09PM  Jazz Securities Designated Activity Company -- Moody's assigns Ba1 to Jazz Pharma's senior secured credit facilities Moody's
06:31AM  3 Biotechs on the FDA's Naughty List That Should Be on Investors' Buy Lists Motley Fool
May-14-18 07:10AM  Free Breakfast Technical Briefing on Intrexon and Three Other Biotech Stocks ACCESSWIRE
May-13-18 11:51PM  Edited Transcript of JAZZ earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-10-18 08:30AM  Jazz Pharmaceuticals to Highlight Breadth of Research in Narcolepsy and Excessive Sleepiness in Obstructive Sleep Apnea at SLEEP 2018 Annual Meeting PR Newswire
May-09-18 04:05PM  Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences PR Newswire +5.93%
10:32AM  Jazz Pharmaceuticals (JAZZ) Q1 Earnings, Sales Top Estimates Zacks
06:00AM  3 Top Biotech Stocks to Buy in May Motley Fool
May-08-18 08:53PM  Jazz Pharmaceuticals to settle U.S. probe for $57 million Reuters
07:39PM  Jazz: 1Q Earnings Snapshot Associated Press
06:24PM  Jazz Pharmaceuticals Sets Aside $57 Million to Settle DOJ Probe Bloomberg
04:05PM  Jazz Pharmaceuticals Announces First Quarter 2018 Financial Results PR Newswire
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops Solriamfetol (JZP-110), which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as in phase II clinical trial for ES associated with Parkinson's disease; Vyxeos for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy. In addition, it evaluates deuterated oxybate for narcolepsy; and sells psychiatry and other products. The company is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COZADD BRUCE CChairman & CEODec 03Sale151.781,000151,780277,688Dec 06 04:35 PM
Young Matthew P.EVP & CFONov 23Sale150.00700105,00032,068Nov 27 04:54 PM
Mulligan SeamusDirectorNov 15Buy144.5650,0007,228,0011,100,868Nov 19 05:32 PM
MILLER MICHAEL PATRICKEVP, US CommercialNov 13Sale149.2720029,85424,972Nov 14 08:08 PM
COZADD BRUCE CChairman & CEONov 01Sale159.451,300207,290278,615Nov 05 06:48 PM
Young Matthew P.EVP & CFOOct 15Sale158.08700110,65832,768Oct 17 04:29 PM
MILLER MICHAEL PATRICKEVP, US CommercialOct 12Sale158.4620031,69225,172Oct 16 04:28 PM
COZADD BRUCE CChairman & CEOOct 01Sale167.991,300218,387279,915Oct 03 04:42 PM
COZADD BRUCE CChairman & CEOSep 21Sale164.361,300213,668281,215Sep 25 06:02 PM
Young Matthew P.EVP & CFOSep 17Sale162.70700113,89033,468Sep 19 05:05 PM
MILLER MICHAEL PATRICKEVP, US CommercialSep 14Sale165.2020033,04025,372Sep 17 06:06 PM
ENRIGHT PATRICK GDirectorSep 06Option Exercise139.1010,1301,409,09426,599Sep 07 04:30 PM
ENRIGHT PATRICK GDirectorSep 06Sale168.7610,1301,709,56516,469Sep 07 04:30 PM
Young Matthew P.EVP & CFOAug 15Sale176.05700123,23534,168Aug 16 06:57 PM
MILLER MICHAEL PATRICKEVP, US CommercialAug 14Sale175.7020035,14025,572Aug 16 04:52 PM
Treacy PaulSVP, Technical OperationsAug 10Sale176.611,309231,18317,458Aug 13 07:03 PM
BERNS PAUL LDirectorAug 10Sale176.61660116,5636,772Aug 13 06:52 PM
Gray PeterDirectorAug 10Sale176.61715126,2778,182Aug 13 06:47 PM
O'Keefe Kenneth WDirectorAug 10Sale176.61660116,5634,450Aug 13 06:42 PM
McSharry Heather AnnDirectorAug 10Sale176.61715126,2767,504Aug 13 06:38 PM
Schnee ElmarDirectorAug 10Sale176.61742131,0456,094Aug 13 06:23 PM
Sohn Catherine A.DirectorAug 10Sale176.61660116,5637,654Aug 13 06:20 PM
ENRIGHT PATRICK GDirectorAug 10Sale175.131,365239,05716,469Aug 13 06:13 PM
Winningham Rick EDirectorAug 10Sale176.61660116,5634,950Aug 13 06:05 PM
RIEDEL NORBERT GDirectorAug 10Sale176.61660116,5636,491Aug 13 07:57 PM
Winningham Rick EDirectorAug 09Option Exercise64.309,000578,65520,094Aug 13 06:05 PM
Winningham Rick EDirectorAug 09Sale176.1615,9792,814,8385,610Aug 13 06:05 PM
COZADD BRUCE CChairman & CEOAug 01Sale173.901,600278,240282,515Aug 03 06:21 PM
Young Matthew P.EVP & CFOJul 16Sale176.06700123,24234,868Jul 18 05:06 PM
MILLER MICHAEL PATRICKEVP, US CommercialJul 13Sale179.1520035,83025,772Jul 17 04:44 PM
COZADD BRUCE CChairman & CEOJul 02Sale170.811,600273,296284,115Jul 05 04:33 PM
Young Matthew P.EVP & CFOJun 15Sale176.99700123,89335,568Jun 19 04:26 PM
MILLER MICHAEL PATRICKEVP, US CommercialJun 14Sale176.5320035,30625,972Jun 18 04:37 PM
Young Matthew P.EVP & CFOJun 01Option Exercise58.725,000293,60041,268Jun 05 06:52 PM
Young Matthew P.EVP & CFOJun 01Sale170.045,000850,21236,268Jun 05 06:52 PM
COZADD BRUCE CChairman & CEOJun 01Sale168.867,0001,182,040285,715Jun 05 06:50 PM
Young Matthew P.EVP & CFOMay 15Sale164.641,420233,78936,203May 16 04:54 PM
MILLER MICHAEL PATRICKEVP, US CommercialMay 14Sale164.6820032,93626,122May 15 05:24 PM
WILSON KAREN JSVP, Finance & PAOMay 11Sale165.003,760620,40015,757May 15 05:27 PM
COZADD BRUCE CChairman & CEOMay 01Sale151.571,000151,570292,542May 03 04:57 PM
Young Matthew P.EVP & CFOApr 16Sale156.01700109,20738,465Apr 18 05:09 PM
MILLER MICHAEL PATRICKEVP, US CommercialApr 13Sale157.4920031,49827,481Apr 13 05:22 PM
WILSON KAREN JSVP, Finance & PAOApr 10Sale155.003,899604,34519,517Apr 12 04:25 PM
COZADD BRUCE CChairman & CEOApr 02Sale150.011,000150,010293,542Apr 04 05:49 PM
Young Matthew P.EVP & CFOMar 15Sale151.22700105,85439,165Mar 19 04:44 PM
MILLER MICHAEL PATRICKEVP, US CommercialMar 14Sale151.1220030,22427,681Mar 16 05:10 PM
COZADD BRUCE CChairman & CEOMar 09Sale150.001,000150,000294,542Mar 13 05:27 PM
Treacy PaulSVP, Technical OperationsMar 06Sale141.4759484,03018,641Mar 07 04:10 PM
Young Matthew P.EVP & CFOMar 06Sale142.361,152163,99839,865Mar 07 04:10 PM
Treacy PaulSVP, Technical OperationsMar 02Sale139.62877122,44619,235Mar 05 04:39 PM
Young Matthew P.EVP & CFOFeb 28Sale148.821,219181,41132,965Feb 28 05:57 PM
COZADD BRUCE CChairman & CEOFeb 28Sale150.001,000150,000262,830Feb 28 05:24 PM
Young Matthew P.EVP & CFOFeb 27Sale145.601,916278,96934,790Feb 28 05:57 PM
MILLER MICHAEL PATRICKEVP, US CommercialFeb 14Sale139.9920027,99821,469Feb 16 05:31 PM
Young Matthew P.EVP & CFOJan 16Sale152.16700106,51238,959Jan 18 05:05 PM
MILLER MICHAEL PATRICKEVP, US CommercialJan 12Sale148.6520029,73021,669Jan 17 04:55 PM
COZADD BRUCE CChairman & CEOJan 12Sale150.003,000450,000273,737Jan 17 04:53 PM